RA Capital Management L.P. Makes New $28.98 Million Investment in ChemoCentryx, Inc. (NASDAQ:CCXI)
RA Capital Management L.P. Makes New $28.98 Million Investment in ChemoCentryx, Inc. (NASDAQ:CCXI)
RA Capital Management L.P. acquired a new stake in ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,155,964 shares of the biopharmaceutical company's stock, valued at approximately $28,980,000.
根据RA Capital Management L.P.提交给美国证券交易委员会的最新Form 13F文件,该公司在第一季度收购了ChemoCentryx,Inc.(CCXI-GET Rating)的新股份。该基金收购了这家生物制药公司1,155,964股股票,价值约28,980,000美元。
Other hedge funds and other institutional investors also recently made changes to their positions in the company. UMB Bank N A MO acquired a new position in shares of ChemoCentryx in the 4th quarter valued at about $37,000. Lazard Asset Management LLC acquired a new position in ChemoCentryx during the 4th quarter worth approximately $60,000. Prospera Financial Services Inc acquired a new position in ChemoCentryx during the 1st quarter worth approximately $46,000. Point72 Hong Kong Ltd acquired a new position in ChemoCentryx during the 4th quarter worth approximately $115,000. Finally, Commerce Bank acquired a new position in ChemoCentryx during the 4th quarter worth approximately $219,000. 81.09% of the stock is owned by institutional investors and hedge funds.
其他对冲基金和其他机构投资者最近也对他们在该公司的头寸进行了调整。UMB Bank N A MO在第四季度收购了ChemoCentryx股票的新头寸,价值约37,000美元。Lazard Asset Management LLC在第四季度收购了ChemoCentryx的一个新头寸,价值约6万美元。普罗斯佩拉金融服务公司在第一季度收购了ChemoCentryx的一个新头寸,价值约4.6万美元。Point72 Hong Kong Ltd在第四季度收购了ChemoCentryx的一个新头寸,价值约115,000美元。最后,商业银行在第四季度获得了ChemoCentryx的一个新头寸,价值约21.9万美元。81.09%的股票由机构投资者和对冲基金持有。
ChemoCentryx Stock Performance
ChemoCentryx股票表现
Shares of CCXI stock traded down $0.05 during trading on Tuesday, hitting $51.45. The company's stock had a trading volume of 21,283 shares, compared to its average volume of 1,904,635. The company has a market cap of $3.67 billion, a PE ratio of -27.23 and a beta of 1.25. The company has a current ratio of 4.54, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $38.94 and a 200-day moving average of $28.58. ChemoCentryx, Inc. has a 52 week low of $14.95 and a 52 week high of $51.78.
在周二的交易中,CCXI的股价下跌了0.05美元,达到51.45美元。该公司股票的成交量为21,283股,而其平均成交量为1,904,635股。该公司市值为36.7亿美元,市盈率为-27.23,贝塔系数为1.25。该公司的流动比率为4.54,速动比率为4.47,债务权益比率为0.02。该业务的50日移动均线切入位在38.94美元,200日移动均线切入位在28.58美元。ChemoCentryx,Inc.的52周低点为14.95美元,52周高位为51.78美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Insider Activity
内幕活动
In other ChemoCentryx news, CFO Susan M. Kanaya sold 19,898 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $50.95, for a total transaction of $1,013,803.10. Following the completion of the transaction, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at $4,652,601.15. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other ChemoCentryx news, CFO Susan M. Kanaya sold 19,898 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $50.95, for a total transaction of $1,013,803.10. Following the sale, the chief financial officer now owns 91,317 shares in the company, valued at $4,652,601.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James L. Tyree sold 10,000 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $50.22, for a total value of $502,200.00. Following the sale, the director now owns 9,138 shares in the company, valued at approximately $458,910.36. The disclosure for this sale can be found here. Insiders sold a total of 213,760 shares of company stock valued at $10,749,838 over the last three months. Corporate insiders own 8.30% of the company's stock.
在ChemoCentryx的其他新闻中,首席财务官Susan M.Kanaya在8月16日(星期二)的一笔交易中出售了19898股ChemoCentryx股票。该股以50.95美元的平均价格出售,总成交金额为1013,803.10美元。交易完成后,首席财务官现在直接持有该公司91,317股股票,价值4,652,601.15美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以在美国证券交易委员会的网站上看到。在ChemoCentryx的其他新闻中,首席财务官Susan M.Kanaya在8月16日(星期二)的一笔交易中出售了19898股ChemoCentryx股票。该股以50.95美元的平均价格出售,总成交金额为1013,803.10美元。出售后,这位首席财务官现在拥有该公司91,317股,价值4652,601.15美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过这个超级链接获得。此外,在8月4日(星期四)的一笔交易中,董事詹姆斯·L·泰里出售了10,000股新浪微博股票。这只股票的平均售价为50.22美元,总价值为502,200.00美元。交易完成后,董事现在拥有该公司9138股,价值约458,910.36美元。此次拍卖的披露信息可在此处找到。过去三个月,内部人士总共出售了213,760股公司股票,价值10,749,838美元。公司内部人士持有该公司8.30%的股份。
ChemoCentryx Profile
ChemoCentryx配置文件
(Get Rating)
(获取评级)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
ChemoCentryx,Inc.是一家生物制药公司,专注于在美国开发和商业化治疗炎症性疾病、自身免疫性疾病和癌症的新药。它提供TAVNEOS(Avacopan),一种口服的选择性C5aR抑制剂,用于治疗严重的抗中性粒细胞胞浆抗体相关小血管炎的成人患者。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- 免费获取StockNews.com关于ChemoCentryx(CCXI)的研究报告
- 这就是现在对标准普尔500指数的预期
- 关于甲骨文的FQ1报告,你需要知道的两件事
- 波动市场的三只价值股
- 3个能源类股接近突破杯形格局
- 这些股息获得者值得在你的投资组合中占有一席之地吗?
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating).
想看看还有哪些对冲基金持有CCXI吗?访问HoldingsChannel.com获取ChemoCentryx,Inc.(纳斯达克代码:CCXI-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChemoCentryx日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ChemoCentryx和相关公司的最新新闻和分析师评级的每日简要摘要。